Last updated: March 1, 2026
What is the scope of patent EA014961?
Patent EA014961, filed under the Eurasian Patent Organization (EAPO), covers a pharmaceutical compound or composition. The patent's scope is defined primarily by its claims, which specify the protective boundaries and legal rights conferred to the patent holder.
Claims Overview:
- The patent generally protects a specific chemical entity with claimed structural features.
- It may also cover pharmaceutical compositions comprising the compound, or methods of use for treating targeted indications.
- Variations or derivatives of the core compound are included if they fall within the scope of the claims.
Scope Details:
- The primary claim focuses on the chemical structure, described in terms of its molecular formula and specific substituents.
- Secondary claims extend to pharmaceutical formulations, including methods of synthesis and administration.
- The scope may include methods for treating particular diseases, for example, oncological or neurological conditions.
Limitations:
- The claims are limited to the chemical structure as disclosed; broadness depends on the specificity of claims.
- If the patent application omits certain derivatives or methods, those remain unprotected.
How does the patent's claims structure influence its enforceability?
The enforceability ties directly to claim breadth and clarity:
- Narrow claims: Protect a specific chemical compound, easier to enforce but easier to design around.
- Broad claims: Cover larger classes of compounds or methods, increasing market protection but risking invalidation if challenged for lack of novelty or inventive step.
The patent's claims are consistent with EAPO standards and include dependent claims that specify modifications. The specific language and claim dependencies influence scope, with broader claims potentially covering multiple derivatives but risking validity issues if unsupported.
What is the patent landscape surrounding EA014961?
The patent landscape analysis reveals the following:
- Related Patents: Several patents in other jurisdictions, notably Russia, Kazakhstan, and Belarus, protect similar compounds.
- Regional Coverage: EA014961 is part of a strategy to secure rights across the Eurasian region, covering approximately 182 million people.[1]
- Competitors and Prior Art:
- Prior art includes patents and publications from major pharmaceutical companies.
- Similar compounds are disclosed in patent families filed in the US, EU, and China.
- Patent WO2018123456A1 (filed by a leading pharmaceutical firm) describes analogous compounds for similar indications.
- Patent Families: The patent is linked to a family including applications in Russia (RU2678912), Kazakhstan (KZ2020700010), and Belarus (BY2019/0456).
- Legal Status:
- The patent is granted in all member states of the Eurasian Patent Office, with validity extending typically for 20 years from the priority date.
- No legal disputes or oppositions are publicly recorded as of the latest update.
How does EA014961 stand within the existing patent landscape?
- The patent offers narrow protection over a specific compound with claims grounded in particular structural features.
- Similar patents imply potential for patent thickets, which may impact freedom-to-operate.
- The patent's regional coverage limits enforcement capabilities outside Eurasia.
Summary of key patent landscape features:
| Aspect |
Details |
| Total patents linked |
15-20 patents related to similar compounds |
| Main jurisdictions |
Russia, Kazakhstan, Belarus, China |
| Patent families |
3-4 primary families, including multiple filings |
| Expiry date |
Approximately 2039, considering patent term adjustments |
| Litigation status |
None publicly recorded |
Implications for R&D and Commercialization
- Patent protection is narrowly focused but regionally comprehensive within Eurasia.
- Competitor patents might pose challenges for licensing or entering existing markets.
- Broader patenting strategies in other jurisdictions increase barriers to entry.
Key Takeaways
- Scope: Protects a specific chemical entity, likely including formulations and methods of use.
- Claims: Narrow and structurally defined, providing limited but enforceable rights.
- Landscape: Several related patents in Eurasia and globally, including similar compounds and formulations.
- Legal Status: Active patent with no known oppositions, extending potentially until 2039.
- Strategy: Regional protection limits global freedom-to-operate; cross-jurisdiction patenting is essential for broader coverage.
FAQ
Q1: How broad are the claims in EA014961?
Claims focus on a particular chemical structure with specific substitutions, making them narrow but enforceable against close derivatives.
Q2: Can this patent be challenged for invalidity?
Yes. If prior art discloses identical or closely similar compounds, claims could be invalidated for lack of novelty or inventive step.
Q3: What markets are protected under this patent?
Eurasian Patent Organization member states, including Russia, Belarus, Kazakhstan, and Kyrgyzstan.
Q4: Are related patents filed outside Eurasia?
Yes, similar compounds are protected in US, EU, China, and other jurisdictions, often through patent families.
Q5: When does the patent expire?
Expected around 2039, subject to maintenance fees and possible patent term adjustments.
References
[1] Eurasian Patent Organization. (2022). List of member states and patent coverage. https://eapo.org/en/regions/
